Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

This phase II trial studies the effect of the combination of ramucirumab and trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or gastroesophageal junction cancer that has spread to other places in the body (advanced). Ramucirumab may damage tumor cells by targeting new blood vessel formation. Trifluridine/tipiracil is a chemotherapy pill and that may damage tumor cells by damaging their deoxyribonucleic acid (DNA). Paclitaxel may block cell growth by stopping cell division which may kill tumor cells. Giving ramucirumab and trifluridine/tipiracil will not be worse than ramucirumab and paclitaxel in treating gastric or gastroesophageal junction cancer.
Phase II
Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics
Paclitaxel, Ramucirumab, TAS-102
Gibson, Mike
Vanderbilt University


18 Years
Inclusion Criteria:

Age >= 18 years

Histological or cytological confirmation of adenocarcinoma of the stomach or gastroesophageal junction

Have locally advanced unresectable or metastatic disease that has progressed = 180 days since last treatment

One or more measurable or nonmeasurable evaluable lesions per Response Evaluation Criteria in Solid Tumors (RECIST)

Planned for second line treatment defined by failing or were intolerant to previous standard chemotherapies containing one or more of the following agents: * Fluoropyrimidine (IV 5-FU or capecitabine) and platinum (cisplatin or oxaliplatin) * Trastuzumab in case of HER2-positive disease * NOTE: For the patients whose disease recurred = 168 days from the last dose of adjuvant anticancer chemotherapy, that adjuvant anticancer chemotherapy is counted as 1 prior chemotherapy line

Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

Ability to swallow oral medications

Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained = 7 days prior to registration)

Platelet count >= 100,000/mm^3 (obtained = 7 days prior to registration)

Hemoglobin >= 9.0 g/dL (obtained = 7 days prior to registration)

Total bilirubin = 1.5 x upper limit of normal (ULN) (obtained = 7 days prior to registration)

Aspartate transaminase (AST) and alanine transaminase (ALT) = 3 x ULN ( = 5.0 x UNL, if with liver metastasis) (obtained = 7 days prior to registration)

International normalized ratio (INR) = 1.5 x ULN, and a partial thromboplastin time (PTT) = 5 seconds above the ULN (unless receiving anticoagulation therapy) (obtained = 7 days prior to registration) * Note: Patients receiving warfarin must be switched to low molecular weight heparin and have achieved stable coagulation profile prior to first dose of protocol therapy * Note: Patients on full-dose anticoagulation must be on a stable dose (minimum duration 14 days) of oral anticoagulant or low molecular weight heparin (LMWH) * Exception: If receiving warfarin, the patient must have an INR = 3.0. For heparin and LMWH there should be no active bleeding (that is, no bleeding within 14 days prior to first dose of protocol therapy) or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices)

Urinary protein is = 1+ on dipstick or routine urinalysis (UA; if urine dipstick or routine analysis is >= 2+, a 24-hour urine collection for protein must demonstrate = 1000 mg of protein in 24 hours to allow participation in this protocol) (obtained = 7 days prior to registration)

Creatinine = 1.5 times the ULN or creatinine clearance (measured via 24-hour urine collection) >= 50 mL/minute (that is, if serum creatinine is >= 1.5 times the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed) (obtained = 7 days prior to registration)

Negative pregnancy test done = 7 days prior to registration, for women of childbearing potential only

Ability to complete questionnaire(s) by themselves or with assistance

Provide informed written consent = 28 days prior to registration

Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)

Because the teratogenicity of ramucirumab is not known, the patient, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods)

Exclusion Criteria:

Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: * Pregnant women * Nursing women * Women of childbearing potential who are unwilling to employ adequate contraception

Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

Previous treatment with TAS-102 or ramucirumab

Previous taxane therapy = 180 days prior to registration

Any grade 3-4 gastrointestinal (GI) bleeding = 90 days prior to registration

History of deep vein thrombosis (DVT), pulmonary embolism (PE), or any other significant thromboembolism (venous port or catheter thrombosis or superficial venous thrombosis are not considered significant) = 90 days prior to registration

Any arterial thromboembolic events, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular accident, or unstable angina, = 180 days prior to registration

Prior history of GI perforation/fistula = 180 days of registration or risk factors for perforation

Serious or nonhealing wound, ulcer, or bone fracture = 28 days prior to registration

Major surgery = 28 days prior to first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement = 7 days prior to registration

Elective or planned major surgery to be performed during the course of the clinical trial

Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. NOTE: Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis

Uncontrolled or poorly-controlled hypertension (>= 150 mmHg systolic or >= 90 mmHg diastolic for >= 4 weeks) despite standard medical management

Immunocompromised and known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial

Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm

Other active malignancy = 3 years prior to registration. EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix. NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer

Receiving chronic antiplatelet therapy, including dipyridamole or clopidogrel, or similar agents. NOTE: Once-daily aspirin use (maximum dose 325 mg/day) is permitted

To learn more about any of our clinical
trials, call 615-936-8422.